Evaluation of Paraoxonase, Arylesterase and Malondialdehyde Levels in Schizophrenia Patients Taking Typical, Atypical and Combined Antipsychotic Treatment.
10.9758/cpn.2016.14.4.345
- Author:
Mehmet GÜNEŞ
1
;
Mehmet Akif CAMKURT
;
Mahmut BULUT
;
Süleyman DEMIR
;
Aslıhan Okan IBILOĞLU
;
Mehmet Cemal KAYA
;
Abdullah ATLI
;
Ibrahim KAPLAN
;
Aytekin SIR
Author Information
1. Department of Psychiatry, Faculty of Medicine, Dicle University, Diyarbakir, Turkey.
- Publication Type:Original Article
- Keywords:
Paraoxonase;
Arylesterase;
Malondialdehyde;
Schizophrenia;
Antipsychotics;
Treatment
- MeSH:
Antipsychotic Agents;
Aryldialkylphosphatase*;
Humans;
Lipid Peroxidation;
Malondialdehyde*;
Oxidative Stress;
Schizophrenia*
- From:Clinical Psychopharmacology and Neuroscience
2016;14(4):345-350
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVE: Human serum paraoxonase (PON1) prevents lipids from peroxidation and functions as an antioxidant mechanism. Malonyldialdehyde (MDA) is the final product of lipid peroxidation and can be used as an indicator of oxidative stress. The aim of this study was to investigate PON1, MDA, and arylesterase (ARY) levels in schizophrenic patients who are taking typical, atypical, or combined (typical and atypical) antipsychotic drug treatment, with respect to those of healthy controls. METHODS: We evaluated 41 patients (11 taking typical antipsychotics, 19 taking atypical antipsychotics, 11 taking combined anti-psychotics) and 43 healthy controls. RESULTS: MDA levels were higher in schizophrenic patients taking typical antipsychotics compared with healthy controls (p=0.001). ARY levels were higher in patients taking atypical antipsychotics compared with healthy controls (p=0.005). PON1 activity was similar in all groups. CONCLUSION: Our results indicate that treatment with typical antipsychotic drugs could be related to increased MDA levels; and antipsychotic medication may increase PON1 levels in schizophrenic patients.
